mRNA Therapeutics and mRNA Vaccines Market (2nd Edition) by Route of Administration (Intravenous, Intramuscular, Intranasal and Others), Therapeutic Area (Infectious Diseases, Oncological Disorders and Other Disorders), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa): Global Trends and Industry Analysis, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    October 2022

  • Pages
    272

  • View Count
    12811

Example Insights

mRNA-Therapeutics-and-Vaccines-Market-Context-thumb mRNA-Therapeutics-and-Vaccines-Market-Development-Pipeline-thumb mRNA-Therapeutics-and-Vaccines-Market-Distribution-by-Phase-of-Development-thumb mRNA-Therapeutics-and-Vaccines-Market-Company-Competitiveness-Analysis-thumb
mRNA-Therapeutics-and-Vaccines-Market-Start-up-Health-Indexing-thumb mRNA-Therapeutics-and-Vaccines-Market-Clinical-Trial-Analysis-thumb mRNA-Therapeutics-and-Vaccines-Market-Patent-Analysis-thumb mRNA-Therapeutics-and-Vaccines-Market-Partnerships-and-Collaborations-thumb
mRNA-Therapeutics-and-Vaccines-Market-Funding-and-Investments-thumb mRNA-Therapeutics-and-Vaccines-Market-Big-Pharma-Players-thumb mRNA-Therapeutics-and-Vaccines-Market-Future-Opportunity-thumb  

Overview

Messenger ribonucleic acid (mRNA) is a type of single-stranded ribonucleic acid (RNA), which helps in transferring genetic information in order to produce proteins. The mRNA encoding instructions for protein synthesis are transferred from a strand of DNA to the ribosomes, where these instructions are translated and processed into functional proteins.  

Q1. How is the research and development (R&D) activity evolving in the mRNA-based drugs industry?
mRNA therapeutics and mRNA vaccines have emerged as a promising alternative to conventional treatment approaches. Post the onset of the COVID-19 pandemic, mRNA therapeutics and mRNA vaccines have garnered significant attention as they have evolved as a revolutionary novel drug class for the treatment of COVID-19, as well as several other diseases, such as infectious diseases, oncological disorders, genetic disorders and other disorders. Subsequently, upon the approval of the first mRNA vaccine under emergency use authorization (EUA), Comirnaty®, in 2020, the field has witnessed a further surge in activity. Since then, two more mRNA-based drugs under EUA, namely (in chronological order of approval year) Spikevax® (December 2020) and GEMCOVAC™-19 (June 2022) have been approved by regulatory authorities. In addition, over 1,000 mRNA therapeutics are being evaluated in various stages of clinical trials for the treatment of multitude of disease indications.  This demonstrates remarkable scientific advancement and therapeutic promise of these ground-breaking drug candidates.

Q2. What are the key advantages offered by mRNA therapeutics and mRNA vaccines?
The ongoing research and development efforts being undertaken in this domain are primarily being driven by the various advantages offered by these molecules, including higher biological efficacy, enhanced potent immunogenicity and versatile delivery platforms at reduced toxicity levels, over other therapeutic modalities. Recent reports highlight the potential benefits related to the use of mRNA; for instance, such products pose no undesirable risk of inadvertent infection and insertional mutagenesis. Additionally, the in vivo half-life of mRNA can be regulated by deploying different modifications and delivery techniques in order to make the drugs more stable and highly translatable, as it is usually degraded by typical cellular activities. Moreover, owing to the high yields of in vitro transcription reactions, the manufacturing of mRNA candidates is believed to be cost-effective, rapid and scalable. 

Q3. What are the current opportunities in the mRNA vaccines and mRNA therapeutics market?
In the past few years, the field of mRNA therapeutics and mRNA vaccines has evolved at a steady pace. In fact, a significant amount of preclinical data has been gathered and multiple human clinical trials have been initiated. Further, over the past decade, major technological innovations and substantial investments have enabled mRNA to become a promising therapeutic tool in the field of vaccine development and protein replacement therapy. With the advent of several mRNA-based technologies, there has been a rise in the development of these therapeutics to target a myriad of disease indications. 

In addition, it is important to highlight the recent opportunities that have been created in this market, post the onset of the COVID-19 pandemic. As mentioned earlier, till date, three mRNA-based vaccines have received approval for the treatment of COVID-19, while a number of such candidates are being evaluated as potential therapies. Moreover, BioNTech and Pfizer have signed contracts to deliver 2.4 billion doses of its approved vaccine, Comirnaty®, by the end of 2022.  The overall success of the mRNA-based therapies and mRNA vaccines against COVID-19 has attracted the interest of several investors, specifically towards small and emerging mRNA focused biotechnology companies.  Further, along with drug developers, the mRNA technology and platform providers are streamlining their existing capabilities to offer a wide range of services to their clients. 

Q4. What are the recent developments and expected trends in the mRNA vaccines and mRNA therapeutics market?
Presently, over 35 companies are engaged in the evaluation of more than 195 mRNA therapeutics and mRNA vaccines, across various stages of development, for a myriad of disease indications. Further, over the coming decade, several promising leads, specifically those exhibiting enhanced efficacy, are anticipated to be commercially launched. Moreover, considering the active involvement of big pharma players, as well as new entrants, the development pipeline of mRNA drugs is likely to grow further. It is also worth highlighting that close to 150 collaborations have been inked between industry / academic stakeholders to advance the development of their proprietary pipeline candidates. Driven by the growing interest of various stakeholders and encouraging clinical research results, the overall mRNA therapeutics and mRNA vaccines market is anticipated to witness consistent growth, till 2035.

Q5. What are the key challenges faced by mRNA drug developers?
Despite the numerous benefits offered by mRNA therapies, developers of these novel products often face challenges related to the stability and targeted delivery of their drug candidates. Some of the other key concerns faced by drug developers include limited availability of expertise, lack of specialized infrastructure, requirement for exorbitant capital investment, and constraints associated with ensuring compliance to good manufacturing practices (GMP). , 

Q6. What are the key value drivers in the mRNA vaccines and mRNA therapeutics market? 
The key value drivers in the mRNA therapeutics and mRNA vaccines market include a significant rise in the overall healthcare expenditure, increased R&D spending, a surge in mRNA-focused research initiatives and a plethora of mRNA technological advancements in the recent past.  

Q7. How is the revenue generation potential associated with mRNA therapeutics and mRNA vaccines likely to evolve in the coming years?
The revenue generation potential associated with the mRNA therapeutics and mRNA vaccines is anticipated to witness a steady growth in the foreseen future. Specifically, in terms of route of administration, the current market is expected to be driven by sales of mRNA therapeutics designed for administration via the intramuscular route, and this trend is unlikely to change in the foreseen future as well. Further, another key segment is represented by mRNA-based therapies targeting infectious diseases, which presently capture a significant share of the global market (in terms of sales-based revenues)

Q8. Who are the key players engaged in the mRNA therapeutics and mRNA vaccines market?
Examples of key players engaged in this domain (which have also been captured in this report) include BioNTec, Chimeron Bio, CureVac, eTheRNA, IMMORNA, Moderna, Omega Therapeutics, RNACure and Stemirna Therapeutics.

Scope of the Report

The “mRNA Therapeutics and mRNA Vaccines Market (2nd Edition) by Route of Administration (Intravenous, Intramuscular, Intranasal and Others), Therapeutic Area (Infectious Diseases, Oncological Disorders and Other Disorders), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa): Global Trends and Industry Analysis, 2022-2035” report features an extensive study of the current market overview and future potential of the mRNA therapeutics and mRNA vaccines market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report features: 

  • A detailed overview of the overall market landscape of mRNA therapeutics and mRNA vaccines, based on several relevant parameters, such as phase of development (marketed, phase III, phase II, phase I / II, phase I, preclinical and discovery), type of drug candidate (mRNA therapeutic and mRNA vaccine), therapeutic area (infectious diseases, oncological disorders, genetic disorders, pulmonary disorders, autoimmune disorders and other disorders), type of delivery system used (lipid nanoparticles, lipopolyplex, liposomes, direct transfer, self-amplifying RNA platform and others), type of molecule encoded (spike protein, glycoprotein, antigen, cytokine, protein coding gene, tumor neoantigen, enzyme, tumor antigen and others) and route of administration (intramuscular, intravenous, intranasal and others).
  • A detailed overview of the current market of players engaged in the development of mRNA therapeutics and mRNA vaccines, along with information on their year of establishment, company size (in terms of number of employees), location of headquarters, regional landscape and key players engaged in this domain.
  • An in-depth company competitiveness analysis of mRNA therapeutics and mRNA vaccines developers based on their portfolio strength (in terms of year of establishment and company size), pipeline strength (in terms of its pipeline maturity and drug administration route) and number of therapeutic areas targeted.
  • Detailed profiles of marketed and late stage (phase III) mRNA therapeutics and mRNA vaccines, along with information on the development timeline of the therapy, current development status, primary target indication, therapeutic area, type of molecule encoded, type of delivery system used, affiliated technology, recent partnerships associated with the drug, clinical trial results related to the drug and other recent developmental.
  • A review of the various mRNA-focused initiatives undertaken by big pharma players (shortlisted on the basis of the revenues generated in 2021), featuring a [A] heat map representation that highlights mRNA therapeutics and mRNA vaccines under development (in partnership with core mRNA-focused entities), along with information on funding amount raised, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), as well as [B] a spider web representation, comparing the initiatives of big pharmaceutical players on the basis of multiple relevant parameters.
  • An analysis of start-ups (established between 2016-2022) engaged in this domain, based on several relevant parameters, such as number of candidates in discovery, preclinical and clinical phases of development, amount raised, number of investors and number of deals inked.
  • An analysis of completed, ongoing and planned clinical studies of mRNA therapeutics and mRNA vaccines, based on several relevant parameters, such as trial registration year, trial status, trial phase, target therapeutic area, study design, type of sponsor / collaborator, leading industry players (in terms of number of trials conducted), enrolled patient population and key geographical regions.
  • An analysis of recent collaborations and partnerships within the mRNA therapeutics and mRNA vaccines industry, based on several relevant parameters, such as year of partnership, type of partnership, targeted therapeutic area, most active players (in terms of number of deals inked) and regional distribution of partnership activity that have been undertaken in this domain, during the period 2013-2022.
  • A detailed analysis of various investments made by players engaged in this domain, during the period 2013-2022, based on several relevant parameters, such as year of funding, type of funding (seed financing, venture capital, IPOs, secondary offerings, debt, grants and other offerings), amount invested, therapeutic area, most active players (in terms of number of funding instances and amount invested) and key investors (in terms of number of funding instances)
  • An in-depth analysis of the various patents that have been filed / granted related to mRNA therapeutics and mRNA vaccines domain, since 2016, based on several relevant parameters, such as type of patent (granted patents, patent applications and others), publication year, geographical region, CPC symbols, leading industry players (in terms of the number of patents filed / granted) and patent valuation.

One of the key objectives of this report was to estimate the existing market opportunity and the future growth potential of the mRNA therapeutics and mRNA vaccines market over the coming years. We have provided an informed estimate on the likely financial evolution of the market in the short to mid-term and long term, for the period 2022-2035. Additionally, the report features the likely distribution of the current and upcoming opportunity segmented across important parameters, such as [A] route of administration (intravenous, intramuscular, intranasal and others), [B] therapeutic area (infectious diseases, oncological disorders and other disorders), and [C] key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa).

In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios of the industry’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Which are the key players engaged in the development of mRNA therapeutics and mRNA vaccines?
  • Which mRNA drug candidates are being evaluated across early and late stages of clinical development?
  • Which are the key therapeutic areas targeted by mRNA therapeutics and mRNA vaccines?
  • Which type of delivery systems are primarily being used for the delivery of mRNA therapeutics and mRNA vaccines?
  • Which are the most active trial sites (in terms of number of clinical studies being conducted) related to mRNA therapeutics and mRNA vaccines?
  • Which companies are actively filing patents in order to drive innovation in the field of mRNA therapeutics and mRNA vaccines?
  • What type of partnership models are commonly adopted by stakeholders in the mRNA therapeutics and vaccine domain?
  • Which are the companies that are investing heavily in this domain?
  • How is the current and future market opportunity likely to be distributed across the various key market segments?

Contents

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. mRNA Therapeutics
3.2.1. Advantages of mRNA Therapeutics
3.2.2. Key Applications of mRNA Therapeutics
3.3. mRNA Vaccines
3.3.1. Advantages of mRNA Vaccines
3.3.2. Key Applications of mRNA Vaccines
3.4. mRNA Delivery Routes
3.5. mRNA Delivery Strategies
3.6. Key Challenges Associated with mRNA Therapeutics and Vaccines
3.7. Future Perspectives

4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. mRNA Therapeutics and Vaccines: Overall Market Overview
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Drug Candidate
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Phase of Development and Therapeutic Area
4.2.5. Analysis by Type of Delivery System Used
4.2.6. Analysis by Type of Molecule Encoded
4.2.7. Analysis by Route of Administration
4.2.8. Analysis by Therapeutic Area and Route of Administration
4.2.9. Analysis by Phase of Development, Therapeutic Area and Route of Administration (Grid Representation)

5. COMPETITIVE LANDSCAPE
5.1. mRNA Therapeutics and Vaccines: List of Developers
5.1.1. Analysis by Year of Establishment
5.1.2. Analysis by Company Size
5.1.3. Analysis by Location of Headquarters
5.1.4. Key Players: Analysis by Number of Drug Candidates
5.1.5. Key Players: Analysis by Number of Drug Candidates and Phase of Development
5.1.6. Key Players: Analysis by Number of Drug Candidates and Therapeutic Area
5.1.7. Analysis by Year of Establishment, Company Size and Location of Headquarters (Heat Map Representation)
5.1.8. mRNA Therapeutics and Vaccines: Analysis by Phase of Development and Location of Headquarters (Regional Landscape)

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Key Assumptions and Parameters
6.3. Methodology
6.4. mRNA Therapeutics and Vaccines Developers: Company Competitive Analysis
6.5. mRNA Therapeutics and Vaccines Developers based in North America
6.6. mRNA Therapeutics and Vaccines Developers based in Europe
6.7. mRNA Therapeutics and Vaccines Developers based in Asia-Pacific and Rest of the World

7. DRUG PROFILES
7.1. Chapter Overview
7.2. BNT162b2 (BioNTech / Pfizer)
7.2.1. Drug Overview

7.3. GEMCOVAC-19 (Gennova)
7.3.1. Drug Overview
7.4. mRNA-1273 (Moderna) 
7.4.1. Drug Overview

7.5. LUNAR-COV19 (Arcturus Therapeutics)
7.5.1. Drug Overview

7.6. CVnCOV (CureVac)
7.6.1. Drug Overview

7.7. mRNA-1010 (Moderna)
7.7.1. Drug Overview

7.8. mRNA-1345 (Moderna)
7.8.1. Drug Overview

7.9. mRNA-1647 (Moderna)
7.9.1. Drug Overview

7.10. ARCoV (Walvax)
7.10.1. Drug Overview

8. BIG PHARMA INITIATIVES
8.1. Chapter Overview
8.2. Scope and Methodology

8.3. mRNA Related Initiatives of Big Pharmaceutical Players
8.3.1. Analysis by Portfolio Diversity
8.3.2. Analysis by Phase of Development
8.3.3. Analysis by Target Therapeutic Areas

8.4. Benchmark Analysis of Big Pharmaceutical Players
8.4.1. Spider Web Analysis: Amgen
8.4.2. Spider Web Analysis: AstraZeneca
8.4.3. Spider Web Analysis: Bayer
8.4.4. Spider Web Analysis: BioNTech
8.4.5. Spider Web Analysis: Eli Lilly
8.4.6. Spider Web Analysis: Gilead Sciences
8.4.7. Spider Web Analysis: GlaxoSmithKline
8.4.8. Spider Web Analysis: Merck
8.4.9. Spider Web Analysis: Moderna
8.4.10. Spider Web Analysis: Novartis
8.4.11. Spider Web Analysis: Novo Nordisk
8.4.12. Spider Web Analysis: Pfizer
8.4.13. Spider Web Analysis: Roche
8.4.14. Spider Web Analysis: Sanofi
8.4.15. Spider Web Analysis: Takeda

9. START-UP HEALTH INDEXING
9.1. Chapter Overview
9.2. Start-ups focused on mRNA Therapeutics and Vaccines
9.2.1. Analysis by Location of Headquarters

9.3. Benchmarking of Start-ups

9.4. Startup-Health Indexing
9.4.1. Analysis by Supplier Strength
9.4.2. Analysis by Pipeline Maturity
9.4.3. Analysis by Pipeline Strength
9.4.4. Analysis by Financial Investments
9.4.5. Analysis by Partnership Activity
9.4.6. Start-ups Health Indexing: Roots Analysis Perspective

10. CLINICAL TRIAL ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. mRNA Therapeutics and Vaccines: Clinical Trial Analysis
10.3.1. Analysis by Trial Registration Year
10.3.2. Analysis by Trial Status
10.3.3. Analysis by Trial Phase
10.3.4. Analysis by Trial Registration Year and Trial Status
10.3.5. Analysis by Trial Registration Year and Trial Phase
10.3.6. Analysis by Trial Status and Trial Phase
10.3.7. Analysis of Enrolled Patient Population by Trial Registration Year
10.3.8. Analysis by Study Design
10.3.9. Analysis by Type of Sponsor / Collaborator
10.3.10. Most Active Players: Analysis by Number of Registered Trials
10.3.11. Analysis by Therapeutic Area
10.3.12. Analysis by Number of Registered Trials and Geography
10.3.13. Analysis by Number of Registered Trials, Trial Status and Geography
10.3.14. Analysis of Enrolled Patient Population by Geography

11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models

11.3. mRNA Therapeutics and Vaccines: Partnerships and Collaborations
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Analysis by Year and Type of Partnership
11.3.4. Analysis by Therapeutic Area
11.3.5. Analysis by Type of Partnership and Therapeutic Area
11.3.6. Most Active Players: Analysis by Number of Partnerships
11.3.7. Regional Analysis
11.3.7.1. Intercontinental and Intracontinental Agreements
11.3.7.2. Local and International Agreements

12. FUNDING AND INVESTMENT ANALYSIS
12.1. Chapter Overview
12.2. Types of Funding
12.3. mRNA Therapeutics and Vaccines: Funding and Investment
12.3.1. Analysis by Cumulative Year-wise Trend of Funding Instances
12.3.2. Analysis by Cumulative Year-wise Trend of Amount Invested
12.3.3. Analysis by Type of Funding
12.3.4. Analysis by Year and Type of Funding
12.3.5. Analysis of Number of Funding Instances and Amount Invested by Therapeutic Area
12.3.6. Analysis of Number of Funding Instances and Amount Invested by Geography (Continent-wise)
12.3.7. Regional Analysis of Number of Funding Instances (Country-wise)
12.3.8. Most Active Players: Analysis by Number of Funding Instances
12.3.9. Most Active Players: Analysis by Total Amount Raised
12.3.10. Most Active Investors: Analysis by Number of Funding Instances
12.3.11. Analysis of Amount Invested by Year and Type of Funding (Grid Representation)

13. PATENT ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. mRNA Therapeutics and Vaccines: Patent Analysis
13.3.1. Analysis by Type of Patent
13.3.2. Analysis by Patent Publication Year
13.3.3. Analysis of Granted Patents by Publication Year
13.3.4. Analysis of Filed Patents by Publication Year
13.3.5. Analysis of Year-wise Filed Patent Applications and Granted Patents
13.3.6. Analysis by Publication Year and Type of Applicant
13.3.7. Analysis by Patent Issuing Authority
13.3.8. Analysis by Patent Age
13.3.9. Analysis by CPC Symbols
13.3.10. Leading Players: Analysis by Number of Patents
13.3.11. Leading Inventors: Analysis by Number of Patents

13.4. mRNA Therapeutics and Vaccines: Patent Benchmarking Analysis
13.4.1. Analysis by Patent Characteristics
13.5. mRNA Therapeutics and Vaccines: Patent Valuation Analysis

14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Methodology

14.3. Global mRNA Therapeutics and Vaccines Market, 2022-2035
14.3.1. mRNA Therapeutics and Vaccines Market: Analysis by Route of Administration, 2022, 2030, 2035
14.3.2. mRNA Therapeutics and Vaccines Market: Analysis by Therapeutic Area, 2022, 2030, 2035
14.3.3. mRNA Therapeutics and Vaccines Market: Analysis by Geography, 2022, 2030, 2035
14.3.3.1. mRNA Therapeutics and Vaccines Market in North America, 2022-2035
14.3.3.2. mRNA Therapeutics and Vaccines Market in Europe, 2022-2035
14.3.3.3. mRNA Therapeutics and Vaccines Market in Asia-Pacific, 2022-2035
14.3.3.4. mRNA Therapeutics and Vaccines Market in Latin America, 2022-2035
14.3.3.5. mRNA Therapeutics and Vaccines Market in Middle East and North Africa, 2022-2035

14.4. mRNA Therapeutics and Vaccines Market: Value Creation Analysis
14.5. mRNA Therapeutics and Vaccines Market: Product-wise Sales Forecasts
14.5.1. COMIRNATY
14.5.1.1. Target Patient Population
14.5.1.2. Sales Forecast
14.5.1.3. Net Present Value
14.5.1.4. Value Creation Analysis

14.5.2. Spikevax
14.5.2.1. Target Patient Population
14.5.2.2. Sales Forecast
14.5.2.3. Net Present Value
14.5.2.4. Value Creation Analysis

14.5.3. GEMCOVAC-19
14.5.3.1. Target Patient Population
14.5.3.2. Sales Forecast
14.5.3.3. Net Present Value
14.5.3.4. Value Creation Analysis

14.5.4. ARCoV
14.5.4.1. Target Patient Population
14.5.4.2. Sales Forecast
14.5.4.3. Net Present Value
14.5.4.4. Value Creation Analysis

14.5.5. CVnCoV
14.5.5.1. Target Patient Population
14.5.5.2. Sales Forecast
14.5.5.3. Net Present Value
14.5.5.4. Value Creation Analysis

14.5.6. ARCT-154
14.5.6.1. Target Patient Population
14.5.6.2. Sales Forecast
14.5.6.3. Net Present Value
14.5.6.4. Value Creation Analysis

14.5.7. mRNA-1647
14.5.7.1. Target Patient Population
14.5.7.2. Sales Forecast
14.5.7.3. Net Present Value
14.5.7.4. Value Creation Analysis

14.5.8. mRNA-1345
14.5.8.1. Target Patient Population
14.5.8.2. Sales Forecast
14.5.8.3. Net Present Value
14.5.8.4. Value Creation Analysis

14.5.9. mRNA-1010
14.5.9.1. Target Patient Population
14.5.9.2. Sales Forecast
14.5.9.3. Net Present Value
14.5.9.4. Value Creation Analysis

15. CONCLUSION

16. INTERVIEW AND SURVEY TRANSCRIPTS
16.1. Chapter Overview
16.2. eTheRNA Immunotherapies
16.2.1. Company Snapshot
16.2.2. Interview Transcript: David Ricketts (Director, Business Development)

17. APPENDIX I: TABULATED DATA

18. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Market Landscape
Figure 2.2 Executive Summary: Clinical Trial Analysis
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investment Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Historical Evolution of mRNA
Figure 3.2 Key Applications of mRNA Therapeutics
Figure 4.1 mRNA Therapeutics and Vaccines: Distribution by Phase of Development
Figure 4.2 mRNA Therapeutics and Vaccines: Distribution by Type of Drug Candidate
Figure 4.3 mRNA Therapeutics and Vaccines: Distribution by Therapeutic Area
Figure 4.4 mRNA Therapeutics and Vaccines: Distribution by Phase of Development and Therapeutic Area
Figure 4.5 mRNA Therapeutics and Vaccines: Distribution by Type of Delivery System Used
Figure 4.6 mRNA Therapeutics and Vaccines: Distribution by Type of Molecule Encoded
Figure 4.7 mRNA Therapeutics and Vaccines: Distribution by Route of Administration
Figure 4.8 mRNA Therapeutics and Vaccines: Distribution by Therapeutic Area and Route of Administration
Figure 4.9 mRNA Therapeutics and Vaccines: Distribution by Phase of Development, Therapeutic Area and Route of Administration
Figure 5.1 mRNA Therapeutics and Vaccines Developers: Distribution by Year of Establishment
Figure 5.2 mRNA Therapeutics and Vaccines Developers: Distribution by Company Size
Figure 5.3 mRNA Therapeutics and Vaccines Developers: Distribution by Location of Headquarters
Figure 5.4 Key Players: Distribution by Number of Drug Candidates
Figure 5.5 Key Players: Distribution by Phase of Development
Figure 5.6 Key Players: Distribution by Therapeutic Area
Figure 5.7 mRNA Therapeutics and Vaccines Developers: Distribution by Year of Establishment, Company Size and Location of Headquarters
Figure 5.8 mRNA Therapeutics and Vaccines Developers: Distribution by Phase of Development and Location of Headquarters
Figure 6.1 Company Competitiveness Analysis: mRNA Therapeutics and Vaccines Developers based in North America
Figure 6.2 Company Competitiveness Analysis: mRNA Therapeutics and Vaccines Developers based in Europe
Figure 6.3 Company Competitiveness Analysis: mRNA Therapeutics and Vaccines Developers based in Asia-Pacific and Rest of the World
Figure 8.1 Big Pharma Players: Distribution of Top Pharmaceutical Companies
Figure 8.2 Big Pharma Players: Distribution by Portfolio Diversity
Figure 8.3 Big Pharma Players: Distribution by Phase of Development
Figure 8.4 Big Pharma Players: Distribution by Target Therapeutic Areas
Figure 8.5 Spider Web Analysis: Amgen
Figure 8.6 Spider Web Analysis: AstraZeneca
Figure 8.7 Spider Web Analysis: Bayer
Figure 8.8 Spider Web Analysis: BioNTech
Figure 8.9 Spider Web Analysis: Eli Lilly
Figure 8.10 Spider Web Analysis: Gilead Sciences
Figure 8.11 Spider Web Analysis: GlaxoSmithKline
Figure 8.12 Spider Web Analysis: Merck
Figure 8.13 Spider Web Analysis: Moderna
Figure 8.14 Spider Web Analysis: Novartis
Figure 8.15 Spider Web Analysis: Novo Nordisk
Figure 8.16 Spider Web Analysis: Pfizer
Figure 8.17 Spider Web Analysis: Roche
Figure 8.18 Spider Web Analysis: Sanofi
Figure 8.19 Spider Web Analysis: Takeda
Figure 9.1 Startup-Health Indexing: Distribution by Location of Headquarters
Figure 9.2 Startup-Health Indexing: Distribution by Supplier Strength
Figure 9.3 Startup-Health Indexing: Distribution by Pipeline Maturity
Figure 9.4 Startup-Health Indexing: Distribution by Pipeline Strength
Figure 9.5 Startup-Health Indexing: Distribution by Financial Investments
Figure 9.6 Startup-Health Indexing: Distribution by Partnership Activity
Figure 9.7 Start-up Health Indexing: Roots Analysis Perspective
Figure 9.8 Start-up Health Indexing: Leading Companies
Figure 10.1 Clinical Trial Analysis: Distribution by Trial Registration Year, Pre-2017-2022
Figure 10.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 10.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 10.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 10.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase
Figure 10.6 Clinical Trial Analysis: Distribution by Trial Status and Trial Phase
Figure 10.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 10.8 Clinical Trial Analysis: Distribution of Trials by Study Design
Figure 10.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 10.10 Most Active Players: Distribution by Number of Registered Trials
Figure 10.11 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 10.12 Clinical Trial Analysis: Distribution by Number of Registered Trials and Geography
Figure 10.13 Clinical Trial Analysis: Distribution by Number of Registered Trials, Trial Status and Geography
Figure 10.14 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Figure 11.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2013-2022
Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 11.4 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 11.5 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
Figure 11.6 Most Active Players: Distribution by Number of Partnerships
Figure 11.7 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 11.8 Partnerships and Collaborations: Local and International Agreements
Figure 12.1 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre-2015 - 2022
Figure 12.2 Funding and Investment Analysis: Cumulative Year-wise Trend of Amount Invested, Pre-2015 - 2022 (USD Million)
Figure 12.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 12.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 12.5 Funding and Investment Analysis: Distribution by Year and Type of Funding
Figure 12.6 Funding and Investment Analysis: Distribution of Instances and Amount Invested by Therapeutic Area
Figure 12.7 Funding and Investment Analysis: Distribution of Instances and Amount Invested by Geography (Continent-wise)
Figure 12.8 Funding and Investment Analysis: Regional Distribution of Instances (Country-wise)
Figure 12.9 Most Active Players: Distribution by Number of Funding Instances
Figure 12.10 Most Active Players: Distribution by Total Amount Raised (USD Million)
Figure 12.11 Most Active Investors: Distribution by Number of Funding Instances
Figure 12.12 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Funding
Figure 13.1 Patent Analysis: Distribution by Type of Patent
Figure 13.2 Patent Analysis: Cumulative Distribution by Patent Publication Year, 2016-2022
Figure 13.3 Patent Analysis: Cumulative Distribution of Granted Patents by Publication Year, 2016-2022
Figure 13.4 Patent Analysis: Cumulative Distribution of Filed Patent Applications by Publication Year, 2016-2022
Figure 13.5 Patent Analysis: Distribution by Year-wise Filed Patent Applications and Granted Patents, 2016-2022
Figure 13.6 Patent Analysis: Cumulative Distribution of Patents by Publication Year and Type of Applicant, 2016-2022
Figure 13.7 Patent Analysis: Distribution by Patent Issuing Authority
Figure 13.8 Patent Analysis: Distribution by Patent Age
Figure 13.9 Patent Analysis: Distribution by CPC Sections
Figure 13.10 Patent Analysis: Leading Industry Players
Figure 13.11 Patent Analysis: Leading Non-Industry Players
Figure 13.12 Leading Inventors: Distribution by Number of Patents
Figure 13.13 Patent Benchmarking: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 13.14 mRNA Therapeutics and Vaccines: Patent Valuation
Figure 14.1 Global mRNA Therapeutics and Vaccines Market, 2022-2035 (USD Million)
Figure 14.2 mRNA Therapeutics and Vaccines Market: Distribution by Route of Administration, 2022, 2035 and 2035
Figure 14.3 mRNA Therapeutics and Vaccines Market: Distribution by Therapeutic Area, 2022, 2030 and 2035
Figure 14.4 mRNA Therapeutics and Vaccines Market: Distribution by Geography, 2022, 2030 and 2035
Figure 14.5 mRNA Therapeutics and Vaccines Market in North America, 2022-2035 (USD Million)
Figure 14.6 mRNA Therapeutics and Vaccines Market in the US, 2022-2035 (USD Million)
Figure 14.7 mRNA Therapeutics and Vaccines Market in Canada, 2022-2035 (USD Million)
Figure 14.8 mRNA Therapeutics and Vaccines Market in Mexico, 2022-2035 (USD Million)
Figure 14.9 mRNA Therapeutics and Vaccines Market in Europe, 2022-2035 (USD Million)
Figure 14.10 mRNA Therapeutics and Vaccines Market in the UK, 2022-2035 (USD Million)
Figure 14.11 mRNA Therapeutics and Vaccines Market in France, 2022-2035 (USD Million)
Figure 14.12 mRNA Therapeutics and Vaccines Market in Germany, 2022-2035 (USD Million)
Figure 14.13 mRNA Therapeutics and Vaccines Market in Italy, 2022-2035 (USD Million)
Figure 14.14 mRNA Therapeutics and Vaccines Market in Spain, 2022-2035 (USD Million)
Figure 14.15 mRNA Therapeutics and Vaccines Market in Rest of Europe, 2022-2035 (USD Million)
Figure 14.16 mRNA Therapeutics and Vaccines Market in Asia-Pacific, 2022-2035 (USD Million)
Figure 14.17 mRNA Therapeutics and Vaccines Market in India, 2022-2035 (USD Million)
Figure 14.18 mRNA Therapeutics and Vaccines Market in China, 2022-2035 (USD Million)
Figure 14.19 mRNA Therapeutics and Vaccines Market in Japan, 2022-2035 (USD Million)
Figure 14.20 mRNA Therapeutics and Vaccines Market in Australia, 2022-2035 (USD Million)
Figure 14.21 mRNA Therapeutics and Vaccines Market in Rest of Asia-Pacific, 2022-2035 (USD Million)
Figure 14.22 mRNA Therapeutics and Vaccines Market in Latin America, 2022-2035 (USD Million)
Figure 14.23 mRNA Therapeutics and Vaccines Market in Middle East and North Africa, 2022-2035 (USD Million)
Figure 14.24 Comirnaty Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.25 Spikevax Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.26 GEMCOVAC-19 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.27 ARCoV Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.28 CVnCoV Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.29 ARCT-154 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.30 mRNA-1345 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.31 mRNA-1647 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.32 mRNA-1010 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 15.1 Concluding Remarks: Overall Market Landscape
Figure 15.2 Concluding Remarks: Partnerships and Collaborations
Figure 15.3 Concluding Remarks: Funding and Investment Analysis
Figure 15.4 Concluding Remarks: Clinical Trial Analysis
Figure 15.5 Concluding Remarks: Patent Analysis
Figure 15.6 Concluding Remarks: Market Forecast and Opportunity Analysis

List Of Tables

Table 4.1 mRNA Therapeutics and Vaccines: Overall Market Overview
Table 4.2 mRNA Therapeutics and Vaccines: Information on Type of Delivery System Used
Table 4.3 mRNA Therapeutics and Vaccines: Information on Type of Molecule Encoded
Table 4.4 mRNA Therapeutics and Vaccines: Information on Route of Administration
Table 5.1 mRNA Therapeutics and Vaccines Developers: List of Companies
Table 7.1 Drug Profile: BNT162b2
Table 7.2 Drug Profile: mRNA-1273
Table 7.3 Drug Profile: GEMCOVAC-19
Table 7.4 Drug Profile: ARCoV
Table 7.5 Drug Profile: LUNAR-COV19
Table 7.6 Drug Profile: CVnCoV
Table 7.7 Drug Profile: mRNA-1010
Table 7.8 Drug Profile: mRNA-1345
Table 7.9 Drug Profile: mRNA-1647
Table 9.1 mRNA Therapeutics and Vaccines Start-ups: Information on Location of Headquarters
Table 11.1 mRNA Therapeutics and Vaccines: List of Partnerships and Collaborations
Table 11.2 mRNA Therapeutics and Vaccines: Information on Type of Agreement (Region-wise and Geography-wise), 2013-2022
Table 12.1 mRNA Therapeutics and Vaccines: List of Funding and Investments
Table 13.1 Patent Analysis: Top CPC Sections
Table 13.2 Patent Analysis: Top CPC Symbols
Table 13.3 Patent Analysis: Top CPC
Table 13.4 Patent Portfolio: Summary of Benchmarking Analysis
Table 13.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 13.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 14.1 mRNA Therapeutics and Vaccines: Expected Launch Year of Advance Stage Drug Candidates
Table 14.2 Comirnaty: Target Patient Population
Table 14.3 Comirnaty: Net Present Value (USD Million)
Table 14.4 Comirnaty: Value Creation Analysis (USD Million)
Table 14.5 Spikevax: Target Patient Population
Table 14.6 Spikevax: Net Present Value (USD Million)
Table 14.7 Spikevax: Value Creation Analysis (USD Million)
Table 14.8 GEMCOVAC-19: Target Patient Population
Table 14.9 GEMCOVAC-19: Net Present Value (USD Million)
Table 14.10 GEMCOVAC-19: Value Creation Analysis (USD Million)
Table 14.11 ARCoV: Target Patient Population
Table 14.12 ARCoV: Net Present Value (USD Million)
Table 14.13 ARCoV: Value Creation Analysis (USD Million)
Table 14.14 CVnCoV: Target Patient Population
Table 14.15 CVnCoV: Net Present Value (USD Million)
Table 14.16 CVnCoV: Value Creation Analysis (USD Million)
Table 14.17 ARCT-154: Target Patient Population
Table 14.18 ARCT-154: Net Present Value (USD Million)
Table 14.19 ARCT-154: Value Creation Analysis (USD Million)
Table 14.20 mRNA-1345: Target Patient Population
Table 14.21 mRNA-1345: Net Present Value (USD Million)
Table 14.22 mRNA-1345: Value Creation Analysis (USD Million)
Table 14.23 mRNA-1647: Target Patient Population
Table 14.24 mRNA-1647: Net Present Value (USD Million)
Table 14.25 mRNA-1647: Value Creation Analysis (USD Million)
Table 14.26 mRNA-1010: Target Patient Population
Table 14.27 mRNA-1010: Net Present Value (USD Million)
Table 14.28 mRNA-1010: Value Creation Analysis (USD Million)
Table 16.1 eTheRNA: Key Highlights
Table 17.1 mRNA Therapeutics and Vaccines: Distribution by Phase of Development
Table 17.2 mRNA Therapeutics and Vaccines: Distribution by Type of Drug Candidate
Table 17.3 mRNA Therapeutics and Vaccines: Distribution by Therapeutic Area
Table 17.4 mRNA Therapeutics and Vaccines: Distribution by Phase of Development and Therapeutic Area
Table 17.5 mRNA Therapeutics and Vaccines: Distribution by Type of Delivery System Used
Table 17.6 mRNA Therapeutics and Vaccines: Distribution by Type of Molecule Encoded
Table 17.7 mRNA Therapeutics and Vaccines: Distribution by Route of Administration
Table 17.8 mRNA Therapeutics and Vaccines: Distribution by Therapeutic Area and Route of Administration
Table 17.9 mRNA Therapeutics and Vaccines Developers: Distribution by Year of Establishment
Table 17.10 mRNA Therapeutics and Vaccines Developers: Distribution by Company Size
Table 17.11 mRNA Therapeutics and Vaccines Developers: Distribution by Location of Headquarters
Table 17.12 Key Players: Distribution by Number of Drug Candidates
Table 17.13 Key Players: Distribution by Phase of Development
Table 17.14 Key Players: Distribution by Therapeutic Area
Table 17.15 Big Pharma Players: Distribution by Portfolio Diversity
Table 17.16 Big Pharma Players: Distribution by Phase of Development
Table 17.17 Big Pharma Players: Distribution by Target Therapeutic Areas
Table 17.18 Startup-Health Indexing: Distribution by Location of Headquarters
Table 17.19 Startup-Health Indexing: Distribution by Supplier Strength
Table 17.20 Startup-Health Indexing: Distribution by Pipeline Maturity
Table 17.21 Startup-Health Indexing: Distribution by Pipeline Strength
Table 17.22 Startup-Health Indexing: Distribution by Financial Investments
Table 17.23 Startup-Health Indexing: Distribution by Partnership Activity
Table 17.24 Clinical Trial Analysis: Distribution by Trial Registration Year, Pre-2017-2022
Table 17.25 Clinical Trial Analysis: Distribution by Trial Status
Table 17.26 Clinical Trial Analysis: Distribution by Trial Phase
Table 17.27 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 17.28 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase
Table 17.29 Clinical Trial Analysis: Distribution by Trial Status and Trial Phase
Table 17.30 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Table 17.31 Clinical Trial Analysis: Distribution by Study Design
Table 17.32 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 17.33 Most Active Players: Distribution by Number of Registered Trials
Table 17.34 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 17.35 Clinical Trial Analysis: Distribution by Number of Registered Trials and Geography
Table 17.36 Clinical Trial Analysis: Distribution by Number of Registered Trials, Trial Status and Geography
Table 17.37 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Table 17.38 Partnerships and Collaborations: Cumulative Year-wise Trend, 2013-2022
Table 17.39 Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.40 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 17.41 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 17.42 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
Table 17.43 Most Active Players: Distribution by Number of Partnerships
Table 17.44 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 17.45 Partnerships and Collaborations: Local and International Agreements
Table 17.46 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre-2015 - 2022
Table 17.47 Funding and Investment Analysis: Cumulative Year-wise Trend of Amount Invested, Pre-2015 - 2022 (USD Million)
Table 17.48 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 17.49 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Table 17.50 Funding and Investment Analysis: Distribution by Year and Type of Funding
Table 17.51 Funding and Investment Analysis: Distribution of Instances and Amount Invested by Therapeutic Area
Table 17.52 Funding and Investment Analysis: Distribution of Instances and Amount Invested by Geography (Continent-wise)
Table 17.53 Funding and Investment Analysis: Regional Distribution of Instances (Country-wise)
Table 17.54 Most Active Players: Distribution by Number of Funding Instances
Table 17.55 Most Active Players: Distribution by Total Amount Raised
Table 17.56 Most Active Investors: Distribution by Number of Funding Instances
Table 17.57 Patent Analysis: Distribution by Type of Patent
Table 17.58 Patent Analysis: Cumulative Distribution by Patent Publication Year, 2016-2022
Table 17.59 Patent Analysis: Cumulative Distribution of Granted Patents by Publication Year, 2016-2022
Table 17.60 Patent Analysis: Cumulative Distribution of Filed Patent Applications by Publication Year, 2016-2022
Table 17.61 Patent Analysis: Distribution by Year-wise Filed Patent Applications and Granted Patents, 2016-2022
Table 17.62 Patent Analysis: Cumulative Distribution of Patents by Publication Year and Type of Applicant, 2016-2022
Table 17.63 Patent Analysis: Distribution by Patent Issuing Authority
Table 17.64 Patent Analysis: Distribution by Patent Age
Table 17.65 Patent Analysis: Leading Industry Players
Table 17.66 Patent Analysis: Leading Non-Industry Players
Table 17.67 Leading Inventors: Distribution by Number of Patents
Table 17.68 mRNA Therapeutics and Vaccines: Patent Valuation
Table 17.69 Global mRNA Therapeutics and Vaccines Market, 2022-2035 (USD Million)
Table 17.70 mRNA Therapeutics and Vaccines Market: Distribution by Route of Administration, 2022, 2030 and 2035
Table 17.71 mRNA Therapeutics and Vaccines Market: Distribution by Therapeutic Area, 2022, 2030 and 2035
Table 17.72 mRNA Therapeutics and Vaccines Market: Distribution by Geography
Table 17.73 mRNA Therapeutics and Vaccines Market in North America, 2022-2035 (USD Million)
Table 17.74 mRNA Therapeutics and Vaccines Market in the US, 2022-2035 (USD Million)
Table 17.75 mRNA Therapeutics and Vaccines Market in Canada, 2022-2035 (USD Million)
Table 17.76 mRNA Therapeutics and Vaccines Market in Mexico, 2022-2035 (USD Million)
Table 17.77 mRNA Therapeutics and Vaccines Market in Europe, 2022-2035 (USD Million)
Table 17.78 mRNA Therapeutics and Vaccines Market in the UK, 2022-2035 (USD Million)
Table 17.79 mRNA Therapeutics and Vaccines Market in France, 2022-2035 (USD Million)
Table 17.80 mRNA Therapeutics and Vaccines Market in Germany, 2022-2035 (USD Million)
Table 17.81 mRNA Therapeutics and Vaccines Market in Italy, 2022-2035 (USD Million)
Table 17.82 mRNA Therapeutics and Vaccines Market in Spain, 2022-2035 (USD Million)
Table 17.83 mRNA Therapeutics and Vaccines Market in Rest of Europe, 2022-2035 (USD Million)
Table 17.84 mRNA Therapeutics and Vaccines Market in Asia-Pacific, 2022-2035 (USD Million)
Table 17.85 mRNA Therapeutics and Vaccines Market in India, 2022-2035 (USD Million)
Table 17.86 mRNA Therapeutics and Vaccines Market in China, 2022-2035 (USD Million)
Table 17.87 mRNA Therapeutics and Vaccines Market in Japan, 2022-2035 (USD Million)
Table 17.88 mRNA Therapeutics and Vaccines Market in Australia, 2022-2035 (USD Million)
Table 17.89 mRNA Therapeutics and Vaccines Market in Rest of Asia-Pacific, 2022-2035 (USD Million)
Table 17.90 mRNA Therapeutics and Vaccines Market in Latin America, 2022-2035 (USD Million)
Table 17.91 mRNA Therapeutics and Vaccines Market in Middle East and North Africa, 2022-2035 (USD Million)
Table 17.92 Comirnaty Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.93 Spikevax Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.94 GEMCOVAC-19 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.95 ARCoV Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.96 CVnCoV Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.97 ARCT-154 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.98 mRNA-1345 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.99 mRNA-1647 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.100 mRNA-1010 Sales Forecast: Base Scenario, Till 2035 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. 8VC
  2. Abu Dhabi Investment Authority
  3. ACM Biolabs
  4. Acuitas Therapeutics
  5. Adium Pharma
  6. African Union
  7. AIM Vaccine
  8. Albany Molecular Research
  9. Alcobra
  10. Aldevron
  11. Alexandria Venture Investments
  12. Alexion Pharmaceuticals
  13. Amazon Web Services
  14. Amgen
  15. Arcturus Therapeutics
  16. ArrowMark Partners
  17. Astellas
  18. Astellas Innovation Management (Subsidiary of Astellas Pharma)
  19. AstraZeneca
  20. Atlas Venture
  21. Avidity Partners
  22. Axcelead
  23. Baden-Württemberg Supply Institution for Doctors, Dentists and Veterinarians
  24. Baidu
  25. Baillie Gifford
  26. Baird Capital
  27. Baupost
  28. Bavarian State Ministry for Economic Affairs, Regional Development and Energy
  29. Baxter BioPharma Solutions
  30. Bayer
  31. BB Biotech
  32. BeiGene
  33. Bill & Melinda Gates Foundation
  34. Biomedical Advanced Research and Development Authority
  35. BioNTech
  36. BIORCHESTRA
  37. Biovac
  38. Black Forest SICAV-SIF
  39. BlueIO
  40. Boehringer Ingelheim
  41. Boehringer Ingelheim Venture Fund
  42. BofA Securities
  43. Boston Biotech Ventures
  44. Brookside Capital
  45. BVCF Management
  46. BVF Partners
  47. Cancer Research Institute
  48. CanSino Biologics
  49. Carlos III National Center for Cardiovascular Research (CNIC)
  50. Catalent
  51. CDH Investments
  52. Central Innovation Programme for SMEs (ZIM)
  53. Changhai Hospital
  54. Charles River
  55. Chartwave
  56. Chiesi Farmaceutici
  57. Chimeron Bio
  58. China Growth Capital
  59. China Merchants Medical and Health Industry Equity Fund
  60. cmRNAbone consortium
  61. Coalition for Epidemic Preparedness Innovations (CEPI)
  62. Codex DNA
  63. Colt Ventures
  64. ConserV Bioscience
  65. Continental Grain Company
  66. Coppel family
  67. Cormorant Asset Management
  68. Co-win Ventures
  69. CPE Yuanfeng
  70. CSPC ZhongQi Pharmaceutical Technology
  71. CureVac
  72. Daiichi Sankyo
  73. Daily Partners
  74. Defense Advanced Research Projects Agency
  75. dievini Hopp Biotech
  76. Duke-NUS Medical School
  77. E&Venture Partners
  78. East Hospital Affiliated to Tongji University
  79. EcoR1 Capital
  80. EDBI
  81. Eli Lilly
  82. ELMA Investments
  83. Emergent BioSolutions
  84. eTheRNA
  85. Ethris
  86. Eurofarma
  87. European Commission
  88. European Investment Bank
  89. European Investment Fund
  90. European Union
  91. Eurostars
  92. Evercore
  93. ExploRNA Therapeutics
  94. Fall Line Capital
  95. Fang Fund Partners
  96. Fareva
  97. Fidelity Management & Research Company
  98. First Affiliated Hospital of Zhengzhou University
  99. Flagship Ventures
  100. Flanders Innovation & Entrepreneurship
  101. Flu Lab
  102. Fosun Pharma
  103. Frazier Life Sciences Public Fund
  104. Fudan University
  105. Fund+
  106. Gavi
  107. Genentech
  108. Genevant Sciences
  109. Genmab
  110. Gennova Biopharmaceuticals (Subsidiary of Emcure Pharmaceuticals)
  111. GenScript ProBio
  112. George Mason University
  113. German Federal Government (Kreditanstalt für Wiederaufbau)
  114. German Federal Ministry of Education and Research
  115. German Pension Fund Baden-Württemberg
  116. Ghent University
  117. Gilead Sciences
  118. GlaxoSmithKline
  119. Government of Argentina
  120. Government of Australia
  121. Government of Brandenburg
  122. Government of Canada
  123. Government of Colombia
  124. Government of Pennsylvania
  125. Government of Peru
  126. Government of South Korea
  127. Government of Taiwan
  128. Government of the Philippines
  129. Government of the Republic of Botswana
  130. Government of UK
  131. Grand Decade Developments
  132. GreenLight Biosciences
  133. Greenwoods Investment
  134. Gritstone bio
  135. Gritstone Oncology
  136. Harvard Medical School
  137. Hatteras Venture Partners
  138. HDT Bio
  139. Hercules Capital
  140. HHF Capital
  141. High Forest Investment
  142. High-Tech Gründerfonds
  143. Honeywell
  144. HongKong Hongrun Investment Development
  145. Hunt Technology Ventures
  146. I-Mab
  147. Image Analysis Group
  148. IMM Investment
  149. Immorna
  150. InnoRNA
  151. InstaDeep
  152. Institut Pasteur
  153. Institute for Life Changing Medicines
  154. Institute of Biomaterial Research of the Helmholtz-Zentrum Geesthacht
  155. International AIDS Vaccine Initiative (IAVI)
  156. Invus
  157. Janssen Pharmaceuticals
  158. Janus Henderson Investors
  159. Jebsen Capital
  160. Jefferies
  161. Jeremy and Hannelore Grantham Environmental Trust
  162. Jiuyou Capital
  163. Johnson & Johnson
  164. Julius Baer
  165. Karolinska Institute
  166. Karolinska University Hospital
  167. Kernal Biologics
  168. Körber
  169. Landeskreditbank Baden-Württemberg – Förderbank
  170. Lapam Capital
  171. Laureus Capital
  172. Leerink Partners
  173. Lewis & Clark AgriFood
  174. Liverna Therapeutics (Acquired by AIM Vaccine)
  175. Longmen Capital
  176. Lonza
  177. LSK Investment
  178. LSP
  179. Ludwig Cancer Research
  180. Lupa Systems
  181. MassChallenge
  182. Matinas BioPharma
  183. MedImmune
  184. Medison Pharma
  185. MedLab Clinical
  186. Merck
  187. Mercurna
  188. Ministry of Health Israel
  189. Mirae Asset
  190. MLS Capital Fund II
  191. Moderna
  192. Monsanto
  193. Morningside
  194. MPM Capital
  195. MRL Ventures
  196. Myeloid Therapeutics
  197. Mymetics
  198. myNEO
  199. National Institutes of Health
  200. Neon Therapeutics
  201. Neurimmune
  202. Newpath Partners
  203. NH Investment & Securities
  204. Novalis LifeSciences
  205. Novartis
  206. Novo Nordisk
  207. Omega Funds
  208. Omega Therapeutics
  209. OrbiMed Advisors
  210. Pantherna Therapeutics
  211. Pfizer
  212. Pfizer Venture Investments
  213. Pharmaceutical Product Development
  214. pHion Therapeutics
  215. Pictet
  216. Platinum Asset Management
  217. PMV
  218. Precision NanoSystems
  219. Providence Therapeutics
  220. PROVIREX
  221. Qatar Investment Authority
  222. Quantum Ventures Korea
  223. RA Capital Management
  224. Recipharm
  225. ReCode Therapeutics
  226. Redmile
  227. Regeneron
  228. Rejuvenation Technologies
  229. Renap
  230. Riesner Verwaltungs
  231. Rivas Capital
  232. RNACure
  233. RNAimmune (Subsidiary of Sirnaomics)
  234. Roche
  235. Rock Springs Capital Management
  236. Rotating Boulder Fund
  237. ROVI
  238. S2G Ventures
  239. Samsung BioLogics
  240. Sanofi
  241. Sanofi Pasteur
  242. SBI Investment
  243. Sequoia Capital
  244. Shanghai Jiao Tong University
  245. Shanghai Junshi Biosciences
  246. Shanghai Walga Biotechnology
  247. Shenwan Hongyuan Capital
  248. Shenzhen Kangtai Biological Products
  249. Shire
  250. SIGMA Group
  251. Silicon Valley Bank
  252. Singapore Government
  253. Sirnaomics
  254. Smilegate Investment
  255. Smooth River
  256. Spinnotec
  257. Spruce Capital Partners
  258. SR One
  259. Stanford University
  260. Steam Athena Capital
  261. Stemirna Therapeutics
  262. Struengmann Family Office
  263. Suzhou Abogen Biosciences
  264. Swiss Government
  265. Tabuk Pharmaceuticals
  266. Takeda
  267. Tao Capital Partners
  268. Temasek
  269. Terra Magnum Capital Partners
  270. Thermo Fisher Scientific
  271. TransCode Therapeutics
  272. Translate Bio
  273. Turkish Republic Ministry of Health
  274. Turn Biotechnologies
  275. Ultragenyx Pharmaceutical
  276. United Nations International Children's Emergency Fund (UNICEF)
  277. University of Münster
  278. University of Pennsylvania
  279. University of Tokyo
  280. US Government
  281. Versant Ventures
  282. Vertex Pharmaceuticals
  283. Viceroy Research
  284. Vida Ventures
  285. Viking Global Investors
  286. Vingroup
  287. VitaDAO
  288. WACKER
  289. Walvax Biotechnology
  290. Wellington Management Company
  291. Widwin Investment
  292. WuXi AppTec
  293. Xeraya Capital
  294. Yale University
  295. Yijing Capital
  296. Zheshang Venture Capital
  297. Ziphius Vaccines
  298. Zipline

Segmentation

Market Segments Details

Forecast Period

  • 2022 – 2035

Area of Expertise

  • mRNA Therapeutics
  • mRNA Vaccines 

Route of Administration

  • Intravenous
  • Intramuscular
  • Intranasal
  • Others

Therapeutic Areas

  • Infectious Diseases
  • Oncological Disorders
  • Other Disorders

Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • MENA
  • Latin America
  • Rest of the World 

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com